Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01461317 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT01461317 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 121 participants.
The verdict
NCT01461317, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
This study is an open-label extension (OLE) trial to evaluate the safety and tolerability of etrolizumab in participants with moderate to severe ulcerative colitis (UC) who were enrolled in the Phase II Study ABS4986g (NCT01336465) and meet the eligibility criteria for entry in the OLE study.
Interventions
- DRUG Etrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2011-11-29 |
| Est. Completion | 2016-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01461317
The ClinicalTrials.gov registry entry for NCT01461317 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etrolizumab is the first listed.
NCT01461317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01461317 about?
NCT01461317 is a clinical study titled "Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis". This study is an open-label extension (OLE) trial to evaluate the safety and tolerability of etrolizumab in participants with moderate to severe ulcerative colitis (UC) who were enrolled in the Phase II Study ABS4986g (NCT01336465) and meet the eligibility criteria for entry in the OLE study.
What is the current status of trial NCT01461317?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2011-11-29. Estimated completion is 2016-08-07.
What interventions are being tested in trial NCT01461317?
The interventions under investigation include: Etrolizumab (DRUG).
Who is sponsoring clinical trial NCT01461317?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.